AAP
LCTX icon

Arax Advisory Partners’s Lineage Cell Therapeutics LCTX Stock Holding History

Arax Advisory Partners’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.7K Buy
5,878
+5,750
+4,492% +$7.95K ﹤0.01% 4442
2026
Q1 		$202 Buy
128
+100
+357% +$169 ﹤0.01% 3536
2025
Q4 		$47 Sell
28
-90
-76% -$156 ﹤0.01% 3926
2025
Q3 		$199 Buy
+118
New +$140 ﹤0.01% 3453

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Arax Advisory Partners's LCTX Position: Q2 2026 in Review

Arax Advisory Partners increased its Lineage Cell Therapeutics (LCTX) stake by 4,492% in Q2 2026, buying an estimated $7.95K and bringing the position to 5,878 shares worth $7.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4442.

Arax Advisory Partners first reported a position in LCTX in Q3 2025 and has held it in 4 quarters since. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Arax Advisory Partners held 5,878 shares of Lineage Cell Therapeutics worth $7.7K as of Q2 2026.
  • Arax Advisory Partners bought 5,750 Lineage Cell Therapeutics shares in Q2 2026, an estimated $7.95K.
  • Lineage Cell Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4442 holding.
  • Arax Advisory Partners first reported a position in Lineage Cell Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.